(2) The use of statins or fenofibrate as, in addition to affecting cholesterol or triglyceride levels, such drugs have been shown to reduce plasma NEFA levels.29,67,68 (3) Targeting fatty acid synthase in order to reduce de novo synthesis of NEFAs – this could be particularly important in cancer-associated thrombosis, as expression of this enzyme is frequently increased in tumour cells.69 (4) Design and administration of a small molecule able to inhibit binding of NEFAs to the FA2 site on HSA, whilst not impairing Zn2+ binding to site A. This evidence concerns the gene FASN and cancer.